{"preliminary_commentary":{"by_channel":{"x_thread":13},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05468489\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"ASTRIDE","nct_id":"NCT05468489","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=astride-nct05468489. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Serplulimab + chemotherapy (carboplatin-etoposide)","label":"Serplulimab + chemotherapy","type":"EXPERIMENTAL"},{"description":"Atezolizumab + chemotherapy (carboplatin-etoposide)","label":"Atezolizumab + chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Extensive Stage Small Cell Lung Cancer"],"enrollment":{"count":200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Serplulimab + chemotherapy (carboplatin-etoposide)","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab + chemotherapy (carboplatin-etoposide)","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-21","lead_sponsor":"Shanghai Henlius Biotech","official_title":"A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-02-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"OS","timeFrame":"A period from randomization through death regardless of causality (approximately up to 24 months)."}],"references":[],"start_date":{"date":"2022-11-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","url":"https://clinicaltrials.gov/study/NCT05468489"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/astride-nct05468489"}